AAA
ANAB icon

Affinity Asset Advisors’s AnaptysBio ANAB Stock Holding History

Affinity Asset Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.8M Sell
826,109
-113,891
-12% -$6.9M 2.52% 10
2026
Q1 		$52.1M Buy
940,000
+495,308
+111% +$26.6M 2.69% 10
2025
Q4 		$21.6M Buy
+444,692
New +$17.3M 1.23% 26

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Asset Advisors's ANAB Position: Q2 2026 in Review

Affinity Asset Advisors reduced its AnaptysBio (ANAB) stake by 12% in Q2 2026, selling an estimated $6.9M and leaving 826,109 shares worth $55.8M. The position accounts for 2.52% of the portfolio, ranked #10.

Affinity Asset Advisors first reported a position in ANAB in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Affinity Asset Advisors held 826,109 shares of AnaptysBio worth $55.8M as of Q2 2026.
  • Affinity Asset Advisors sold 113,891 AnaptysBio shares in Q2 2026, an estimated $6.9M.
  • AnaptysBio made up 2.52% of Affinity Asset Advisors's portfolio in Q2 2026, its #10 holding.
  • Affinity Asset Advisors first reported a position in AnaptysBio in Q4 2025 and has held it in 3 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.